Zealand Pharma Announces Financial Results for the First Half of 2022
Company Announcement No. 34 / 2022 Interim report for H1 2022 Zealand Pharma Announces Financial Results for the First Half...
Pharmaceutical
Allied Corp Successfully Ships 1728kgs of Colombian-Grown Commercial Cannabis Flower to Switzerland
Allied Corp is the first company to successfully ship commercial cannabis flower from Colombia to an international market.Allied Corp has...
Landos Biopharma Reports Second Quarter 2022 Results and Provides Business Update
Positive Top-Line Results From NX-13 Phase 1b Trial in Ulcerative Colitis Demonstrate a Favorable Safety and Tolerability Profile Across Range...
Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments
Validive® Phase 2b/3 VOICE Trial Continues Adding Sites in the U.S. and Europe and Enrolling Patients Toward Interim Analysis Anticipated...
F-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Previously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an...
89bio Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Reported positive topline results from ENTRIGUE Phase 2 trial of pegozafermin in severe hypertriglyceridemia patients; initiation of Phase...
Comera Life Sciences to Present Topline Results of SEQURUS-2 Study at 14th Annual Bioprocessing Summit
WOBURN, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA) (“Company” or “Comera”), a life...
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation
MIAMI, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently...
RAPT Therapeutics Reports Second Quarter 2022 Financial Results
Company maintains strong cash position of $207.3 millionSOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc....
Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2022
Menlo Park, California, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today...
Abeona Therapeutics Reports Second Quarter 2022 Financial Results
Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline...
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results
Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the...
Innovation1 Biotech Appoints Chief Scientific Officer Andrew L. Salzman, M.D. to its Board of Directors
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Innovation1 Biotech Inc. (OTCQB: IVBT) (“Innovation1” or the “Company”), a small molecule...
Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments
BALTIMORE, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative...
CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides Business Update
Conference Call Scheduled for Today at 8:30 a.m. Eastern TimeBERKELEY HEIGHTS, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc....
Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- Topline Data Expected First Quarter 2023 -DUBLIN, Ireland and FORT WASHINGTON, Pa., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Nabriva...
Kala Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-- Plan to Initiate Phase 2/3 Trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED) in 4Q 2022; Topline Data...
Vistin Pharma ASA: Invitation to Q2 2022 conference call
Oslo, Norway, 11 August 2022 Vistin Pharma ASA will release its second quarter and YTD 2022 results on Friday 19th of...
Werewolf Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Highlights
- FDA granted IND clearance for lead candidate WTX-124 for evaluation as a treatment for advanced solid tumors - -...